1. Continuous Glucose Monitoring (CGM):

Improved CGM devices now offer more accurate and real-time data, making it easier for patients and healthcare providers to monitor glucose levels continuously. These devices are becoming smaller and more comfortable to wear.

2. Wearable Technology:

New wearable devices not only track glucose levels but also integrate with smartphones to provide comprehensive health data, including trends and alerts for abnormal glucose levels.

3. Artificial Intelligence (AI):

AI-driven tools are being used to analyze large datasets from CGM and other sources to predict diabetes risk and complications more accurately.

4. Biomarker Research:

Advances in identifying biomarkers are helping in the early detection of diabetes. These biomarkers can indicate a predisposition to the disease before traditional symptoms appear.

5. Non-Invasive Testing:

Research is ongoing into non-invasive methods for glucose testing, such as using optical sensors or analyzing sweat, which could reduce the need for finger-prick tests.

6. Integrated Health Platforms:

Digital health platforms now offer integrated solutions that combine glucose monitoring, diet tracking, and exercise data to provide a holistic view of a patient’s health, facilitating better management and early diagnosis.

These advancements are improving early detection, patient comfort, and overall management of diabetes. As of 2024, the diagnostic criteria for diabetes largely remain consistent with previous guidelines, but there have been ome refinements:

1. Hemoglobin A1c (HbA1c):

The standard threshold for diagnosing diabetes is still an HbA1c level of 6.5% or higher. However, there is increasing emphasis on using HbA1c in conjunction with other indicators for a more comprehensive assessment.

2. Fasting Plasma Glucose (FPG):

The cutoff for diabetes diagnosis remains at 126 mg/dL (7.0 mmol/L) or higher.

3. Oral Glucose Tolerance Test (OGTT):

The diagnostic threshold for diabetes continues to be a 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher after a 75g glucose load.

4. Continuous Glucose Monitoring (CGM):

While not a replacement for traditional tests, CGM data is increasingly used to provide additional context and confirm diagnosis, especially in borderline cases.

5. Emerging Biomarkers:

Research is ongoing into new biomarkers that could aid in diagnosis, but these are not yet standard practice.

Overall, while traditional lab test boundaries remain, there is a greater emphasis on integrating multiple data sources for a more nuanced diagnosis.

Chief Executive Officer (CEO)

Dr. Payam Izadpanahi

Radiation Oncology Specialist, MD.

Business Developer

Dr. Arash Omidtabrizi

Ophthalmologist, Vitreoretinal Fellowship, MD.

Chief Scientific Operator (CSO)

Dr. Shima Ardalan

Doctor of Medicine, Obstetrics and Gynecologist, MD.

Resaercher in Diabetic Patients

Chief Operational Operator (COO)

Dr. SeyyedMorteza JafarzadehFadaki

Psychiatrist, MD.

Chair of the Khorasan Branch of Iranian Pyschiatic Association

Chief Technical Operator (CTO)

Dr. Leila Mansourian

Bachelor, master’s and PhD of Computer science

University lecturer, researcher, programmer and AI expert

Machine Learning Developer

Dr. Babak Esmaeilpour Ghouchani

Ph.D, Network, Parallel and Distributed systems

Assistant Professor, Ghouchan Azad University

Research Team

Alireza Akhavan Rezayat, MD.

Urologist MD

Associate professor of urology Mashhad university of medical sciences

Research Team

Dr. Fatemeh Hosseinzadeh

Psychiatrist, MD.

Medical Council of the Islamic Republic of Iran